Skip to main content
Erschienen in: European Child & Adolescent Psychiatry 6/2009

01.06.2009 | ORIGINAL CONTRIBUTION

Executive dysfunction in treated phenylketonuric patients

verfasst von: Dr. Bahare Azadi, Arshia Seddigh, Mehdi Tehrani-Doost, Javad Alaghband-Rad, Mahmoud Reza Ashrafi

Erschienen in: European Child & Adolescent Psychiatry | Ausgabe 6/2009

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Executive function deficits have been described in early and continuously treated patients with phenylketonuria (PKU). The aim of this study was to examine performance on executive function tasks of treated patients with PKU diagnosed by 2 years of age.

Patients and methods

Ten patients with PKU and normal intelligence score who were diagnosed before the age of 2 years and subsequently treated continuously, were compared with 15 typically developing control children on a battery of neuropsychological tests, including the tower of London (TOL), continuous performance test (CPT), and Stroop test.

Results

PKU cases showed significantly poorer performance on the TOL task compared to the control group with the difference being significant in the first three levels of the test. With the CPT, PKU cases had significantly more omission errors than control subjects. On the Stroop test there was no statistically significant difference between the groups. No significant correlation was found between the concurrent serum phenylalanine (Phe) level and results of the executive tests in PKU patients.

Conclusion

This study identified executive dysfunction in early-treated PKU patients with normal IQ, particularly in the planning and attention domains. Further studies are required to compare the results with those from other neurodevelopmental disorders such as ADHD and autism, to establish whether the pattern of findings is specific to PKU.
Literatur
1.
Zurück zum Zitat Arnold GL, Vladutiu CJ, Orlowski CC, Blakely EM, DeLuca J (2004) Prevalence of stimulant use for attentional dysfunction in children with phenylketonuria. J Inherit Metab Dis 27(2):137–143PubMedCrossRef Arnold GL, Vladutiu CJ, Orlowski CC, Blakely EM, DeLuca J (2004) Prevalence of stimulant use for attentional dysfunction in children with phenylketonuria. J Inherit Metab Dis 27(2):137–143PubMedCrossRef
2.
Zurück zum Zitat Baieli S, Pavone L, Meli C, Fiumara A, Coleman M (2003) Autism and phenylketonuria. J Autism Dev Disord 33(2):201–204PubMedCrossRef Baieli S, Pavone L, Meli C, Fiumara A, Coleman M (2003) Autism and phenylketonuria. J Autism Dev Disord 33(2):201–204PubMedCrossRef
3.
Zurück zum Zitat Davidson MC, Amso D, Anderson LC, Diamond A (2006) Development of cognitive control and executive functions from 4 to 13 years: evidence from manipulations of memory, inhibition, and task switching. Neuropsychologia 44(11):2037–2078PubMedCrossRef Davidson MC, Amso D, Anderson LC, Diamond A (2006) Development of cognitive control and executive functions from 4 to 13 years: evidence from manipulations of memory, inhibition, and task switching. Neuropsychologia 44(11):2037–2078PubMedCrossRef
4.
Zurück zum Zitat Diamond A (1994) Phenylalanine levels of 6–10 mg/dl may not be as benign as once thought. Acta Paediatr 83(Suppl 407):89–91CrossRef Diamond A (1994) Phenylalanine levels of 6–10 mg/dl may not be as benign as once thought. Acta Paediatr 83(Suppl 407):89–91CrossRef
5.
Zurück zum Zitat Diamond A, Prevor MB, Callender G, Druin D (1997) Prefrontal cortex cognitive deficits in children treated early and continuously for PKU. Monogr Soc Res Child Dev 62(4):1–208CrossRef Diamond A, Prevor MB, Callender G, Druin D (1997) Prefrontal cortex cognitive deficits in children treated early and continuously for PKU. Monogr Soc Res Child Dev 62(4):1–208CrossRef
6.
Zurück zum Zitat Diamond A (2001) A model system for studying the role of dopamine in the prefrontal cortex during early development in humans: early and continuously treated phenylketonuria. In: Handbook of developmental cognitive neuroscience. MIT Press, Cambridge, pp 433–472 Diamond A (2001) A model system for studying the role of dopamine in the prefrontal cortex during early development in humans: early and continuously treated phenylketonuria. In: Handbook of developmental cognitive neuroscience. MIT Press, Cambridge, pp 433–472
7.
Zurück zum Zitat DeRoche K, Welsh M (2008) Twenty-five years of research on neurocognitive outcomes in early-treated phenylketonuria: intelligence and executive function. Dev Neuropsychol 33(4):474–504PubMedCrossRef DeRoche K, Welsh M (2008) Twenty-five years of research on neurocognitive outcomes in early-treated phenylketonuria: intelligence and executive function. Dev Neuropsychol 33(4):474–504PubMedCrossRef
8.
Zurück zum Zitat Feldmann R, Denecke J, Pietsch M, Grenzebach M, Weglage J (2002) Phenylketonuria: no specific frontal lobe-dependent neuropsychological deficits of early-treated patients in comparison to diabetic patients. Pediatr Res 51:761–765PubMed Feldmann R, Denecke J, Pietsch M, Grenzebach M, Weglage J (2002) Phenylketonuria: no specific frontal lobe-dependent neuropsychological deficits of early-treated patients in comparison to diabetic patients. Pediatr Res 51:761–765PubMed
9.
Zurück zum Zitat Følling I (1994) The discovery of phenylketonuria. Acta Pediatr Suppl 407:4–10CrossRef Følling I (1994) The discovery of phenylketonuria. Acta Pediatr Suppl 407:4–10CrossRef
10.
Zurück zum Zitat Griffiths P, Campbell R, Robinson P (1998) Executive function in treated phenylketonuria as measured by the one-back and two-back versions of the continuous performance test. J Inherit Metab Dis 21:125–135PubMedCrossRef Griffiths P, Campbell R, Robinson P (1998) Executive function in treated phenylketonuria as measured by the one-back and two-back versions of the continuous performance test. J Inherit Metab Dis 21:125–135PubMedCrossRef
11.
Zurück zum Zitat Happé F, Booth R, Charlton R, Hughes C (2006) Executive function deficits in autism spectrum disorders and attention-deficit/hyperactivity disorder: examining profiles across domains and ages. Brain Cogn 61(1):25–39PubMedCrossRef Happé F, Booth R, Charlton R, Hughes C (2006) Executive function deficits in autism spectrum disorders and attention-deficit/hyperactivity disorder: examining profiles across domains and ages. Brain Cogn 61(1):25–39PubMedCrossRef
12.
Zurück zum Zitat Hooper SR, Hatton D, Sideris J, Sullivan K, Hammer J, Schaaf J, Mirrett P, Ornstein PA, Bailey DP Jr (2008) Executive functions in young males with fragile X syndrome in comparison to mental age-matched controls: baseline findings from a longitudinal study. Neuropsychology 22(1):36–47PubMedCrossRef Hooper SR, Hatton D, Sideris J, Sullivan K, Hammer J, Schaaf J, Mirrett P, Ornstein PA, Bailey DP Jr (2008) Executive functions in young males with fragile X syndrome in comparison to mental age-matched controls: baseline findings from a longitudinal study. Neuropsychology 22(1):36–47PubMedCrossRef
13.
Zurück zum Zitat Koch R, Burton B, Coldwell J (2000) A 15-year follow-up report on participants in the collaborative study of children treated for Phenylketonuria (PKUCS 1967–1984): paper presented at the consensus development conference on phenylketonuria (PKU): screening and management. National Institutes of Health, Bethesda Koch R, Burton B, Coldwell J (2000) A 15-year follow-up report on participants in the collaborative study of children treated for Phenylketonuria (PKUCS 1967–1984): paper presented at the consensus development conference on phenylketonuria (PKU): screening and management. National Institutes of Health, Bethesda
14.
Zurück zum Zitat Koochmeshgi J, Bagher A, Hosseini Mazinani SM (2002) Incidence of phenylketonuria in Iran estimated from consanguineous marriages. J Inherit Metab Dis 25:80–81PubMedCrossRef Koochmeshgi J, Bagher A, Hosseini Mazinani SM (2002) Incidence of phenylketonuria in Iran estimated from consanguineous marriages. J Inherit Metab Dis 25:80–81PubMedCrossRef
15.
Zurück zum Zitat Leuzzi V, Pansini M, Sechi E, Chiarotti F, Carducci CL, Levi G, Antonozzi I (2004) Executive function impairment in early-treated PKU subjects with normal mental development. J Inherit Metab Dis 27:115–125PubMedCrossRef Leuzzi V, Pansini M, Sechi E, Chiarotti F, Carducci CL, Levi G, Antonozzi I (2004) Executive function impairment in early-treated PKU subjects with normal mental development. J Inherit Metab Dis 27:115–125PubMedCrossRef
16.
Zurück zum Zitat Luciana M, Sullivan J, Nelson OA (2001) Associations between phenylalanine to tyrosine ratios and performance on tests of neuropsychological function in adolescents treated early and continuously for phenylketonuria. Child Dev 71:1637–1652CrossRef Luciana M, Sullivan J, Nelson OA (2001) Associations between phenylalanine to tyrosine ratios and performance on tests of neuropsychological function in adolescents treated early and continuously for phenylketonuria. Child Dev 71:1637–1652CrossRef
17.
Zurück zum Zitat Mazzocco MM, Nord AM, Doornick WV, Greene CL, Kovar CG, Pennington BF (1994) Cognitive development among children with early-treated phenylketonuria. Dev Neuropsychol 10:133–151CrossRef Mazzocco MM, Nord AM, Doornick WV, Greene CL, Kovar CG, Pennington BF (1994) Cognitive development among children with early-treated phenylketonuria. Dev Neuropsychol 10:133–151CrossRef
18.
Zurück zum Zitat McKean CM (1972) The effects of high phenylalanine concentrations on serotonin and catecholamine metabolism in the human brain. Brain Res 47:469–476PubMedCrossRef McKean CM (1972) The effects of high phenylalanine concentrations on serotonin and catecholamine metabolism in the human brain. Brain Res 47:469–476PubMedCrossRef
19.
Zurück zum Zitat Miller LP, Pardridge WM, Braun LD, Oldendorf WH (1985) Kinetic constants for blood–brain barrier amino acid transport in conscious rats. J Neurochem 45:1427–1432PubMedCrossRef Miller LP, Pardridge WM, Braun LD, Oldendorf WH (1985) Kinetic constants for blood–brain barrier amino acid transport in conscious rats. J Neurochem 45:1427–1432PubMedCrossRef
20.
Zurück zum Zitat Porrino LJ, Goldman-Rakic PS (1982) Brainstem innervation of prefrontal and anterior cingulate cortex in the rhesus monkey revealed by retrograde transport of HRP. J Comp Neurol 205:63–76PubMedCrossRef Porrino LJ, Goldman-Rakic PS (1982) Brainstem innervation of prefrontal and anterior cingulate cortex in the rhesus monkey revealed by retrograde transport of HRP. J Comp Neurol 205:63–76PubMedCrossRef
21.
Zurück zum Zitat Rezvani I (2000) Defects in metabolism of aminoacids—phenylalanine. Nelson textbook of pediatrics, 16th edn. Philadelphia, PA: W.B. Saunders Company, pp 329–333 Rezvani I (2000) Defects in metabolism of aminoacids—phenylalanine. Nelson textbook of pediatrics, 16th edn. Philadelphia, PA: W.B. Saunders Company, pp 329–333
22.
Zurück zum Zitat Ris MD, William SE, Hunt MM, Berry HK, Leslie N (1994) Early- treated phenylketonuria: adult neuropsychologic outcome. J Pediatr 124:388–392PubMedCrossRef Ris MD, William SE, Hunt MM, Berry HK, Leslie N (1994) Early- treated phenylketonuria: adult neuropsychologic outcome. J Pediatr 124:388–392PubMedCrossRef
23.
Zurück zum Zitat Schmidt E, Rupp A, Burgard P, Pietz J, Weglage J, Sonneville L (1994) Sustained attention in adult phenylketonuria: the influence of the concurrent phenylalanine-blood-level. J Clin Exp Neuropsychol 16(5):681–688PubMedCrossRef Schmidt E, Rupp A, Burgard P, Pietz J, Weglage J, Sonneville L (1994) Sustained attention in adult phenylketonuria: the influence of the concurrent phenylalanine-blood-level. J Clin Exp Neuropsychol 16(5):681–688PubMedCrossRef
24.
Zurück zum Zitat Scriver CR, Kaufman S, Eisensmith RC, Woo SLCL (1995) The hyperphenylalaninemias. In: Scriver CR, Baudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 7th edn. McGraw-Hill, New York, pp 1015–1075 Scriver CR, Kaufman S, Eisensmith RC, Woo SLCL (1995) The hyperphenylalaninemias. In: Scriver CR, Baudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 7th edn. McGraw-Hill, New York, pp 1015–1075
25.
Zurück zum Zitat Scriver CR, Kaufman S (2000) The hyperphenylalaninemias: phenylalanine hydroxylase deficiency. In: Scriver CR, Baudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 9th edn. McGraw-Hill, New York, pp 1015–1037 Scriver CR, Kaufman S (2000) The hyperphenylalaninemias: phenylalanine hydroxylase deficiency. In: Scriver CR, Baudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 9th edn. McGraw-Hill, New York, pp 1015–1037
26.
Zurück zum Zitat Seddigh A, Azadi B, Ebrahimi M, Ghafarizadeh A, Koochmeshgi J, Hosseini-Mazinani SM (2001). Prevalence of hyperphenylalaninemia in the Iranian institutionalized developmentally delayed. J Inherit Metab Dis July 24 (suppl. 1) Seddigh A, Azadi B, Ebrahimi M, Ghafarizadeh A, Koochmeshgi J, Hosseini-Mazinani SM (2001). Prevalence of hyperphenylalaninemia in the Iranian institutionalized developmentally delayed. J Inherit Metab Dis July 24 (suppl. 1)
27.
Zurück zum Zitat Shallice T (1982) Specific impairments of planning. Philos Trans R Soc Lond Ser B 298:199–209CrossRef Shallice T (1982) Specific impairments of planning. Philos Trans R Soc Lond Ser B 298:199–209CrossRef
28.
Zurück zum Zitat Stemerdink NBA, Molen MW, Kalverboer AF, Vander Meere JJ, Huisman J, De Jong LW, Slijper FME, Verkerk PH, Van Spronsen FJ (1999) Prefrontal dysfunction in early and continuously treated phenylketonuria. Dev Neuropsychol 16(1):29–57CrossRef Stemerdink NBA, Molen MW, Kalverboer AF, Vander Meere JJ, Huisman J, De Jong LW, Slijper FME, Verkerk PH, Van Spronsen FJ (1999) Prefrontal dysfunction in early and continuously treated phenylketonuria. Dev Neuropsychol 16(1):29–57CrossRef
29.
Zurück zum Zitat Stemerdink NB (2000) Comments on neuropsychological approaches to treatment policy issues in phenylketonuria. Eur J Pediatr 159(Suppl 2):S82–S86 Stemerdink NB (2000) Comments on neuropsychological approaches to treatment policy issues in phenylketonuria. Eur J Pediatr 159(Suppl 2):S82–S86
30.
Zurück zum Zitat Stroop JR (1935) Studies of interference in serial verbal reactions. J Exp Psychol 18:622–643CrossRef Stroop JR (1935) Studies of interference in serial verbal reactions. J Exp Psychol 18:622–643CrossRef
31.
Zurück zum Zitat Welsh MC, Pennington BF, Ozonoff S, Rouse B, McCabe ERB (1990) Neuropsychology of early-treated phenylketonuria: specific executive function deficits. Child Dev 61:1697–1713PubMedCrossRef Welsh MC, Pennington BF, Ozonoff S, Rouse B, McCabe ERB (1990) Neuropsychology of early-treated phenylketonuria: specific executive function deficits. Child Dev 61:1697–1713PubMedCrossRef
32.
Zurück zum Zitat Welsh M, Pennington B (2000) Phenylketonuria. In: Yeates KO, Ris MD, Taylor HG (eds) Pediatric neuropsychology, 1st edn. The Guilford Press, New York, pp 275–299 Welsh M, Pennington B (2000) Phenylketonuria. In: Yeates KO, Ris MD, Taylor HG (eds) Pediatric neuropsychology, 1st edn. The Guilford Press, New York, pp 275–299
33.
Zurück zum Zitat Williamson M, Dobson JC, Koch R (1977) Collaborative study of children treated for Phenylketonuria: study design. Pediatrics 60:815–821PubMed Williamson M, Dobson JC, Koch R (1977) Collaborative study of children treated for Phenylketonuria: study design. Pediatrics 60:815–821PubMed
34.
Zurück zum Zitat White DA, Nortz MA, Mandernach T, Huntington K, Steiner R (2002) Age-related working memory impairments in children with prefrontal dysfunction associated with phenylketonuria. J Int Neuropsychol Soc 8:1–11PubMedCrossRef White DA, Nortz MA, Mandernach T, Huntington K, Steiner R (2002) Age-related working memory impairments in children with prefrontal dysfunction associated with phenylketonuria. J Int Neuropsychol Soc 8:1–11PubMedCrossRef
Metadaten
Titel
Executive dysfunction in treated phenylketonuric patients
verfasst von
Dr. Bahare Azadi
Arshia Seddigh
Mehdi Tehrani-Doost
Javad Alaghband-Rad
Mahmoud Reza Ashrafi
Publikationsdatum
01.06.2009
Erschienen in
European Child & Adolescent Psychiatry / Ausgabe 6/2009
Print ISSN: 1018-8827
Elektronische ISSN: 1435-165X
DOI
https://doi.org/10.1007/s00787-009-0738-8

Weitere Artikel der Ausgabe 6/2009

European Child & Adolescent Psychiatry 6/2009 Zur Ausgabe

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.